Natco Pharma Share Price Today (NATCOPHARM)
TODAY IN ONE LINE
Closed at ₹972.25 (−0.79%); delivery 46.2%. Market opens 9:15 IST. · as of 16:08 IST
With a market cap of ₹17,378.14 Cr., it trades at a P/E of 12.39. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Natco Pharma flags
Key strengths and potential risks.
Green Flags
- ●High Capital EfficiencyROCE of 17.1% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 16.9%
- ●Healthy Operating MarginsOPM is structurally strong at 35.2%
- ●Reasonable ValuationTrading at a moderate P/E of 11.7x
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 34.1% YoY
- ●Sales ContractionQuarterly sales dropped 39.5% YoY
- ●FII SellingFII holding decreased by 1.43% QoQ
- ●Rising Receivables vs SalesReceivables grew 10.8% outpacing sales growth of 10.8%
What changed recently?
Recent events, corporate actions, and announcements.
Natco Pharma Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Natco Pharma Limited, framed against the sector median so the premium or discount is obvious at a glance.
Natco Pharma Limited trades at a P/E of 12.39× and P/B of 1.91×, against the Healthcare sector median P/E of 44.58×.
Valuation
Profitability
Growth
Financial Health
Natco Pharma Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Natco Pharma Limited — derived from the live tape, not yesterday's close.
Natco Pharma Limited last traded at ₹972.25 with an intraday range of ₹966.5–₹983.5 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹972.25| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1015.67 | +43.42 | +4.47% |
| R3 | 998.67 | +26.42 | +2.72% |
| R2 | 991.08 | +18.83 | +1.94% |
| R1 | 981.67 | +9.42 | +0.97% |
| PIVOT | 974.08 | 1.83 | 0.19% |
| CURRENT | 972.25 | — | — |
| S1 | 964.67 | -7.58 | -0.78% |
| S2 | 957.08 | -15.17 | -1.56% |
| S3 | 947.67 | -24.58 | -2.53% |
| S4 | 930.67 | -41.58 | -4.28% |
NATCOPHARM is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹971–₹983.5
Trading Inside opening range
Natco Pharma Limited financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Natco Pharma Limited, switchable between annual and quarterly views, consolidated or standalone.
Natco Pharma Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹17,378.14 Cr. and reported EPS of ₹79.24.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 2,202 | 2,095 | 1,915 | 2,052 | 1,945 | 2,707 | 3,999 | 4,430 | 4,078 |
| Other Income | 40 | 130 | 107 | 104 | 99 | 105 | 128 | 355 | 298 |
| Total Income | 2,242 | 2,225 | 2,022 | 2,156 | 2,044 | 2,812 | 4,127 | 4,784 | 4,376 |
| Cost of Goods Sold (COGS) | 411 | 354 | 382 | 511 | 561 | 627 | 717 | 690 | 691 |
| Gross Profit | 1,791 | 1,740 | 1,533 | 1,541 | 1,384 | 2,080 | 3,282 | 3,740 | 3,388 |
| +Operating Expenses | 863 | 946 | 951 | 935 | 1,120 | 1,144 | 1,531 | 1,544 | 1,951 |
| EBITDA | 928 | 795 | 583 | 606 | 264 | 936 | 1,751 | 2,196 | 1,437 |
| +Non-Operating Expenses | 82 | 100 | 121 | 130 | 160 | 178 | 206 | 259 | 243 |
| Profit Before Tax (PBT) | 887 | 825 | 569 | 580 | 202 | 862 | 1,674 | 2,291 | 1,491 |
| +Tax Expense | 192 | 182 | 111 | 137 | 32 | 147 | 285 | 408 | 119 |
| Total Profit for Period | 695 | 642 | 458 | 442 | 170 | 715 | 1,388 | 1,883 | 1,419 |
| Less: Non-controlling Interests | -1 | -2 | -3 | 2 | — | — | — | -2 | — |
| Net Profit (Owner's PAT) | 696 | 644 | 461 | 441 | 170 | 715 | 1,388 | 1,885 | 1,419 |
| Earnings Per Share (EPS) | 37.74 | 35.24 | 25.31 | 24.18 | 9.31 | 39.20 | 77.51 | 105.26 | 79.20 |
| Diluted Shares Outstanding (Nos.) | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 |
| +Additional Disclosures | 1,760 | 1,745 | 1,818 | 2,098 | 2,452 | 2,580 | 3,185 | 3,156 | 3,910 |
| Sales Growth % | — | -4.88 | -8.57 | 7.16 | -5.23 | 39.20 | 47.72 | 10.77 | -7.93 |
| YoY Sales Growth % | — | -4.88 | -8.57 | 7.16 | -5.23 | 39.20 | 47.72 | 10.77 | -7.93 |
| Material Cost % | 18 | 16 | 17 | 18 | 27 | 18 | 13 | 12 | 15 |
| Employee Cost % | 15 | 17 | 20 | 20 | 23 | 18 | 13 | 13 | 17 |
| Other Cost % | 24 | 28 | 30 | 25 | 35 | 24 | 25 | 21 | 31 |
| OPM % | 42 | 38 | 30 | 30 | 14 | 35 | 44 | 50 | 35 |
| Tax % | 22 | 22 | 19 | 24 | 16 | 17 | 17 | 18 | 8 |
| Profit Growth % | — | -7.44 | -28.49 | -4.32 | -61.44 | 320.76 | 94.09 | 35.81 | -24.76 |
| Gross Margin % | 81.33 | 83.09 | 80.07 | 75.08 | 71.16 | 76.83 | 82.08 | 84.43 | 83.07 |
| EBITDA Margin % | 42.16 | 37.95 | 30.42 | 29.54 | 13.55 | 34.56 | 43.80 | 49.58 | 35.22 |
| Interest Coverage Ratio | 55.99 | 36.98 | 22.46 | 36.79 | 6.83 | 53.23 | 81.49 | 82.04 | 33.51 |
| Ebit | 862 | 714 | 483 | 489 | 121 | 772 | 1,565 | 1,961 | 1,230 |
Natco Pharma segment analysis: revenue and profit mix.
Disclosed business segments at Natco Pharma with their share of revenue and profit, switchable between consolidated and standalone reporting.
Natco Pharma discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Natco Pharma Limited.
Our AI distills the core fundamental drivers supporting Natco Pharma Limited, the risks that threaten it, and the exact valuation or growth triggers that should make you re-evaluate.
Natco Pharma Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Operating margin 30.16% significantly outpaces pharmaceutical peer average of 22.86%.
ROCE 17.10% demonstrates solid capital efficiency and strong asset utilization.
ROE 16.90% reflects robust profitability relative to shareholder equity deployed.
P/E 11.70x trades substantially below peer median 23.65x, indicating undervaluation.
Promoter holding 49.41% ensures stable governance and minority shareholder alignment.
Key Risks.
TTM revenue declined 39.6%, signaling significant top-line contraction and demand weakness.
Latest quarterly EPS declined 34.1% YoY despite operational efficiency, earnings volatility.
Quarterly profit fell 34.1% YoY, reflecting sharp earnings deterioration in recent quarter.
FII holdings eased from 17.94% to 14.09%, signals foreign investor caution and reduced confidence.
Total debt ₹714 Cr limits financial flexibility during prolonged revenue downturns or crises.
Flip Conditions.
Trim if P/E re-rates above 16 (~0.4× the sector multiple of 44.6). The valuation cushion thins from there.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Exit if ROE slips below 12%. The operating engine is no longer compounding capital efficiently.
Income thesis breaks if the dividend is cut or yield falls below 0.26%.
Natco Pharma Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Natco Pharma Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Natco Pharma Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Natco Pharma Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Natco Pharma Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Natco Pharma Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Natco Pharma Limited stood at 46.2% of traded volume, against a 20-day average of 42.2%.
Natco Pharma announcements: results, concalls, ratings, M&A.
Filings Natco Pharma sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Natco Pharma files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 134 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Natco Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Outcome of Board Meeting
Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on July 08, 2026.
Change in Management
We would like to inform you that in accordance with the provisions of Regulation 30 read with Schedule III of SEBI (Listing Obligations and…
Retirement
Natco Pharma Limited has informed the Exchange about Mr. Nadella Malleswara Rao, Vice President - Operations, Pharma Division Kothur of the Company…
Trading Window
Natco Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,…
Investor decks & rating reports.
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Natco Pharma dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Natco Pharma has declared, sequenced by announce and record date.
Natco Pharma corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Natco Pharma insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Natco Pharma as reported to SEBI — buying and selling signals from the people who know the business best.
Natco Pharma insider activity below tracks 15 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| SATYA VANI NANNAPANENI | Insider | 09 Mar 2026 | buy | +45.0 K | ₹4.51 Cr. | ₹1,001.33 |
| SANJAY NANNAPANENI | Insider | 09 Mar 2026 | buy | +70.0 K | ₹7.12 Cr. | ₹1,017.31 |
| SATYA VANI NANNAPANENI | Insider | 09 Mar 2026 | buy | +45.0 K | ₹4.51 Cr. | ₹1,001.33 |
| SANJAY NANNAPANENI | Insider | 09 Mar 2026 | buy | +70.0 K | ₹7.12 Cr. | ₹1,017.31 |
| SATYA VANI NANNAPANENI | Insider | 09 Mar 2026 | buy | +45.0 K | ₹4.51 Cr. | ₹1,001.33 |
| SANJAY NANNAPANENI | Insider | 09 Mar 2026 | buy | +70.0 K | ₹7.12 Cr. | ₹1,017.31 |
| PRAGNYA RAO DONTHINENI | Insider | 10 Jun 2025 | buy | +100 | ₹86,500 | ₹865.00 |
| SANJAY NANNAPANENI | Insider | 26 Mar 2025 | buy | +2.87 L | — | — |
| VENKATA SATYA SWATHI KANTAMANI | Insider | 20 Mar 2025 | sell | −50.0 K | — | — |
| RAJEEV NANNAPANENI | Insider | 20 Mar 2025 | sell | −50.0 K | — | — |
About Natco Pharma Limited: business, sector, key facts.
What Natco Pharma Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Natco Pharma Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: NATCOPHARM, BSE: 524816.
NATCO Pharma Limited is a global pharmaceutical company with a diverse business model encompassing the development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates. Their operations span India, the United States, and other international markets, showcasing a significant reach in the pharmaceutical industry.
A core component of NATCO's business is the production and sale of finished dosage formulations targeting a wide range of therapeutic areas. These formulations are particularly strong in oncology, addressing various cancers including those affecting the blood, liver, kidney, lung, brain, breast, and ovary. Beyond oncology, they also offer products for cardiology and diabetology, specifically targeting conditions like hypertension, stable angina, and congestive heart failure (CHF).
In addition to finished formulations, NATCO Pharma is a significant player in the API market. They manufacture APIs across several therapeutic categories, mirroring the focus of their finished dosage formulations. These categories include oncology, central nervous system treatments, pain management solutions, and cardiovascular care medications. This vertical integration, controlling both API and formulation production, gives them a strategic advantage in the market.
Further diversifying their portfolio, NATCO Pharma provides specialized products in orthopedics, notably bisphosphonates in both oral and injectable forms. They also cater to gastroenterology needs with novel drugs targeting chronic hepatitis B and C. Furthermore, the company offers contract manufacturing services, leveraging their manufacturing expertise to provide services for other pharmaceutical entities.
Beyond human pharmaceuticals, NATCO Pharma extends its reach into the agrochemical sector. They offer a range of solutions for biological pest management, providing tools to control insects, diseases, and weeds across various crops. This expansion into agrochemicals diversifies their revenue streams and demonstrates their adaptability within the broader chemical industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
Questions investors ask about Natco Pharma Limited (NATCOPHARM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Natco Pharma Limited (NATCOPHARM)?
The current share price of Natco Pharma Limited (NATCOPHARM) is ₹972.25. Today, the stock has declined by ₹7.70 (0.79%), trading in a range of ₹966.5 to ₹983.5. The stock opened at ₹978.9 with a trading volume of 2,99,826 shares.
02Is Natco Pharma Limited stock a good investment for long-term?
Natco Pharma Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹17,378.14 crores, P/E ratio of 12.39, ROE of 16.90%, and ROCE of 17.10%. The dividend yield stands at 0.52%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Natco Pharma Limited stock?
The 52-week high price of Natco Pharma Limited (NATCOPHARM) is ₹1,226.8, while the 52-week low is ₹789. Currently trading at ₹972.25, the stock is 41.9% away from its 52-week low and 20.7% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Natco Pharma Limited stock at the current price?
Whether to buy Natco Pharma Limited stock at ₹972.25 depends on multiple factors. The stock is currently trading with a P/E ratio of 12.39 and P/B ratio of 1.91. Today's performance shows a loss of 0.79%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Natco Pharma Limited and when is the next dividend?
Natco Pharma Limited offers a dividend yield of 0.52%, which means for every ₹100 invested at the current price of ₹972.25, you can expect to receive approximately ₹0.52 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Natco Pharma Limited?
Natco Pharma Limited's key financial metrics include: P/E Ratio: 12.39, P/B Ratio: 1.91, ROE: 16.90%, ROCE: 17.10%, Dividend Yield: 0.52%, EPS: ₹79.24, Book Value: ₹514.92, and Debt-to-Equity: 0.00. The company's market cap stands at ₹17,378.14 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Natco Pharma Limited stock performing today in the market?
Natco Pharma Limited stock opened at ₹978.9 and is currently trading at ₹972.25, showing a decline of ₹7.70 (0.79%). The intraday high is ₹983.5 and low is ₹966.5. The trading volume stands at 2,99,826 shares, indicating moderate market participation today.
08What is the P/E ratio of Natco Pharma Limited and what does it indicate?
Natco Pharma Limited has a Price-to-Earnings (P/E) ratio of 12.39, which means investors are willing to pay ₹12.39 for every ₹1 of earnings. With an EPS of ₹79.24, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Natco Pharma Limited (NATCOPHARM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.